Halozyme Therapeutics announced that argenx received approval from Japan’s Ministry of Health, Labour and Welfare, or MHLW, for VYVDURA injection co-formulated with Halozyme’s ENHANZE drug delivery technology for subcutaneous, or SC, use for the treatment of adult patients with generalized myasthenia gravis, or gMG, who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies. The approval of VYVDURA is based on positive results from the Phase 3 ADAPT-SC study. ADAPT-SC established the efficacy of VYVDURA by demonstrating a reduction in percent change from baseline in total immunoglobulin G levels comparable to VYVGART IV in adult gMG patients. ADAPT-SC was a bridging study to the Phase 3 ADAPT study, which formed the basis for approval of VYVGART in Japan in January 2022. VYVDURA is the brand name in Japan for what is branded as VYVGART Hytrulo in the U.S.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
- Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE
- Halozyme announces Roche receives EC marketing authorization of Tecentriq SC
- Halozyme to Host Investor Business Forum and Long-Term Outlook Call
- Halozyme price target lowered to $59 from $61 at Morgan Stanley
- Halozyme price target lowered to $45 from $46 at Goldman Sachs
